GlassScriptPhysician profile
Peter S Yotseff
NPI 1417959073
$3,069.12
in general payments reported to CMS, 2019-2025
22 companies · $1,301 in 2025
The $1,301 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $552 · 2020: $260 · 2021: $384 · 2022: $237 · 2023: $190 · 2024: $145 · 2025: $1,301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,636.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,635.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $626.03 | 2019-2025 | Viberzi, Linzess |
| Janssen Biotech, INC. | $500.44 | 2021-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $348.02 | 2019-2025 | Xifaxan, Plenvu |
| Braintree Laboratories, INC. | $230.93 | 2019-2023 | Sutab, Suflave |
| Gilead Sciences, INC. | $217.16 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $188.26 | 2025 | Entyvio, Eohilia, Gattex |
| Aimmune Therapeutics, INC. | $142.54 | 2025 | Zenpep, Vowst |
| Redhill Biopharma INC. | $141.84 | 2020-2022 | |
| Ardelyx, INC. | $115.44 | 2025 | Ibsrela |
| Boston Scientific Corporation | $89.60 | 2019-2025 | Watchman Flx |
| Ipsen Biopharmaceuticals, INC | $86.21 | 2025 | Iqirvo |
| Phathom Pharmaceuticals, INC. | $75.78 | 2024 | Voquezna |
| Intercept Pharmaceuticals, INC. | $52.30 | 2019-2020 | |
| Madrigal Pharmaceuticals | $49.75 | 2025 | Rezdiffra |
| Exact Sciences Corporation | $42.31 | 2023-2024 | Cologuard Collection Kit |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $37.06 | 2025 | |
| Fresenius Kabi USA, LLC | $30.82 | 2024 | |
| Pfizer INC. | $24.18 | 2025 | |
| Ferring Pharmaceuticals INC. | $21.53 | 2020 | |
| Coloplast Corp | $17.75 | 2025 | |
| Ironwood Pharmaceuticals, INC | $17.34 | 2022 | |
| Allergan, INC. | $13.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Yotseff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.